Market revenue in 2024 | USD 2,631.0 million |
Market revenue in 2030 | USD 4,952.6 million |
Growth rate | 11.1% (CAGR from 2024 to 2030) |
Largest segment | Mammalian |
Fastest growing segment | Non-mammalian |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Mammalian, Non-mammalian |
Key market players worldwide | Boehringer Ingelheim, Lonza Group Ltd, Innovent Biologics Inc, Rentschler Biopharma SE, JRS Pharma, AGC Inc, AGC Biologics, Probiogen, FUJIFILM Holdings Corp, Toyobo Co Ltd, Samsung Electronics Co Ltd, Thermo Fisher Scientific Inc, WuXi Biologics (Cayman) Inc, AbbVie Inc, Novartis AG ADR, Catalent Inc, ADMA Biologics Inc, Pfizer Inc, Siegfried Holding AG, Cambrex, Binex |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biopharmaceuticals contract manufacturing market will help companies and investors design strategic landscapes.
Mammalian was the largest segment with a revenue share of 56.42% in 2024. Horizon Databook has segmented the India biopharmaceuticals contract manufacturing market based on mammalian, non-mammalian covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the India biopharmaceuticals contract manufacturing market , including forecasts for subscribers. This country databook contains high-level insights into India biopharmaceuticals contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account